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INT ROD UCT ION
Multiple myeloma (MM) is a malignant condition that evolves 
from monoclonal gammopathy of undetermined significance 
(MGUS) and corresponds to the expansion of abnormal plas‑
mocytes in the BM (Palumbo and Anderson, 2011). Autol‑
ogous stem cell transplantation remains a good option for 
treating this disease; however, all patients will unavoidably re‑
lapse. Therefore, considerable efforts have been devoted to the 
development of new therapeutic options for the treatment of 
patients suffering from MM. Although drugs such as lenalid‑
Multiple myeloma (MM) evolves from a premalignant condition known as monoclonal gammopathy of undetermined signifi-
cance (MGUS). However, the factors underlying the malignant transformation of plasmocytes in MM are not fully character-
ized. We report here that Eµ-directed expression of the antiapoptotic Bcl-B protein in mice drives an MM phenotype that 
reproduces accurately the human disease. Indeed, with age, Eµ-bcl-b transgenic mice develop the characteristic features of 
human MM, including bone malignant plasma cell infiltration, a monoclonal immunoglobulin peak, immunoglobulin deposit in 
renal tubules, and highly characteristic bone lytic lesions. In addition, the tumors are serially transplantable in irradiated wild-
type mice, underlying the tumoral origin of the disease. Eµ-bcl-b plasmocytes show increased expression of a panel of genes 
known to be dysregulated in human MM pathogenesis. Treatment of Eµ-bcl-b mice with drugs currently used to treat patients 
such as melphalan and VEL CADE efficiently kills malignant plasmocytes in vivo. Finally, we find that Bcl-B is overexpressed in 
plasmocytes from MM patients but neither in MGUS patients nor in healthy individuals, suggesting that Bcl-B may drive MM. 
These findings suggest that Bcl-B could be an important factor in MM disease and pinpoint Eµ-bcl-b mice as a pertinent model 
to validate new therapies in MM.
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omide (REV LIM ID) and bortezomib (VEL CADE) have sig‑
nificantly improved the overall survival rates of patients, MM 
remains an incurable disease, and there is an urgent need for 
new therapies (Strobeck, 2007; Ludwig et al., 2010).
Among the six human antiapoptotic Bcl‑2 family pro‑
teins (Bcl‑2 [BCL2], Bcl‑XL [BCL2L1], Mcl‑1 [MCL1], 
Bcl‑W [BCL2L2], Bfl‑1 [BCL2A1], and Bcl‑B [BCL2L10]; 
Adams and Cory, 1998), Bcl‑B was the last antiapoptotic 
member to be identified, and its physiological function is only 
partially understood (Ke et al., 2001; Zhai et al., 2003). Bcl‑B 
is expressed predominantly in normal human B lymphocytes 
and is pathologically overexpressed in malignant plasma cells 
(PCs) and many types of solid tumors such as prostate, mam‑
mary, colorectal, and lung carcinomas (Luciano et al., 2007; 
Krajewska et al., 2008). Mice lack the bcl‑b gene; however, 
the closest homologue (Diva/Boo) is predominantly ex‑
pressed in ovary and testis and exhibits a proapoptotic rather 
than an antiapoptotic phenotype (Inohara et al., 1998).
Pangenomic studies have been extensively used to iso‑
late genes that are differentially expressed in PCs from healthy 
donors versus MGUS and MM patients (Claudio et al., 2002; 
Davies et al., 2003; De Vos et al., 2003; Carrasco et al., 2006). 
None of these studies identified the bcl‑b gene as a candidate 
promoting the genesis and progression of MM. However, a 
recent report showed that ubiquitination and proteasomal 
turnover dictate the expression level of the Bcl‑B protein and 
thereby its antiapoptotic activity (Beverly et al., 2012; van de 
Kooij et al., 2013; Rooswinkel et al., 2014). Consequently, 
determination of the Bcl‑B protein level appears to be the 
only reliable approach for evaluating its oncogenic potential.
The generation of specific mouse models of MM is not 
only an important challenge but also a prerequisite for better 
characterization and understanding of the molecular mecha‑
nisms involved in MM pathogenesis and the progression from 
MGUS to MM. In addition, the availability of mouse models 
that accurately recapitulate MM could be of considerable in‑
terest for the validation of new therapeutic strategies for this 
disease. However, attempts to develop such models (3′KE‑
bcl‑xL, Igh‑c‑myc Eµ‑c‑maf) have generally yielded B cell 
malignancies displaying immature phenotypes or plasmacy‑
tomas rather than MM (Linden et al., 2004; Park et al., 2005; 
Morito et al., 2011). Several other animal models of MM 
(Eµ‑xbp‑1s, 3′KE‑bcl‑xL/Eµ‑c‑myc, bcl‑xL × imyc) have 
been reported but do not recapitulate all of the characteristics 
of human MM from the clinical, pathological, and genetic 
points of view (Cheung et al., 2004; Boylan et al., 2007; Car‑
rasco et al., 2007). Only the vk*myc mouse model, in which 
the activation of c‑myc oncogene occurs sporadically through 
the physiological somatic hypermutation (SHM) process, ful‑
fills most of the biological and genetic criteria of an ideal 
mouse model of MM (Chesi et al., 2008).
In the present study, we identify the pathophysiological 
function of Bcl‑B for the first time. Of note, we show that 
specific overexpression of Bcl‑B in the B cell compartment 
drives an MM‑like disease in transgenic mice that recapitulates 
the main features of the human pathology, including a unique 
IgG monoclonal peak driven by specific immunoglobulin re‑
arrangements, PC infiltration in the BM, anemia, lytic bone 
lesions, and kidney immunoglobulin deposits. Unlike previ‑
ously characterized MM mouse models, in which penetrance 
was relatively low, 100% of Eµ‑bcl‑b mice develop the disease. 
In addition, Eµ‑bcl‑b mice exhibit increased expression of 
proteins involved in the regulation of B cell proliferation and 
plasmocyte differentiation, including Xbp‑1s.
The discovery that Bcl‑B could be an important factor 
in PC homeostasis that can drive an MM‑like disease in mice 
may have important clinical implications.
RES ULTS
Bcl-B is predominantly expressed 
in the BM of MM patients
We previously reported Bcl‑B overexpression in histological 
BM sections from MM patients (Luciano et al., 2007; Kra‑
jewska et al., 2008). To confirm Bcl‑B protein expression, we 
used a dedicated flow cytometry assay (Cluzeau et al., 2012). 
Fig. 1 A shows an example of Bcl‑B protein expression mea‑
surement by flow cytometry in an MGUS patient and an 
MM patient with 3.6% and 28.2% of medullar plasmocytes, 
respectively. We found that most of the plasmocytes from the 
MM patient highly expressed the Bcl‑B protein, whereas a 
negligible proportion of the plasmocytes from the MGUS 
patient weakly expressed the Bcl‑B protein. In patients with 
newly diagnosed MM (n = 18), 20–100% of sorted CD138+ 
BM cells were positive for Bcl‑B, whereas only a very small 
percentage (0–10%) of CD138+ BM cells from healthy donors 
(n = 3) and MGUS patients (n = 20) were positive for this 
protein (Fig.  1 B). The level of Bcl‑B expression was next 
analyzed by Western blot using plasmocytes from two healthy 
donors, three MGUS patients, and eight patients with newly 
diagnosed MM. All MM patients expressed Bcl‑B, whereas the 
protein was almost undetectable in healthy donors and MGUS 
patients (Fig. 1 C). We finally examined different MM cell lines 
for the expression of Bcl‑B, Bcl‑2, and Mcl‑1 because these 
two latter Bcl‑2 family members were previously reported to 
be important for MM pathogenesis (Spets et al., 2002; Go‑
mez‑Bougie et al., 2004; Wuillème‑Toumi et al., 2005; Morales 
et al., 2011). The level of Bcl‑B expression was homogeneous 
in all of the MM cell lines, whereas significant variation was 
observed for Bcl‑2 and Mcl‑1 expression from one cell line to 
another (Fig. 1, D and E, top). In the corresponding MM cell 
lines, we also examined the expression of Bcl‑B at the RNA 
level. Although there was not a perfect correlation between 
the mRNA level and the protein expression, amplification of 
Bcl‑B mRNA was observed in most cell lines (Fig. 1, D and E, 
bottom).We also detected homogeneous expression of Bcl‑B 
in all B cell lymphoma cell lines tested that was equivalent in 
intensity to that detected in MM. Interestingly, the Bcl‑B pro‑
tein was not detected in two myeloid cell lines (not depicted).
These results are in agreement with previous studies 
that have demonstrated that the expression level of Bcl‑B 
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Figure 1. Bcl-B protein is predominantly expressed in the BM of patients suffering from MM and is widely expressed in human MM cell lines. 
(A) Representative cytometric profiles as examples of Bcl-B–positive PC quantification by flow cytometry analysis of BM cells from an MGUS and an MM 
patient. Total BM cells were quantified, and Bcl-B protein expression was measured by gating the CD138-positive fraction corresponding to medullar plas-
mocytes. NR Ig, nonrelevant rabbit Ig. (B) The percentage of Bcl-B–positive PCs was quantified by flow cytometry analysis of BM cells from healthy donors (n 
= 3), MGUS patients (n = 20), and patients with newly diagnosed MM (n = 18). P-values were determined by one-way ANO VA. NS, no significant difference 
was observed. **, P < 0.01. Results are expressed as the mean ± SD. (C) PCs were isolated from the BM of healthy donors (lanes 1 and 2), MGUS patients 
(lanes 3–5), and MM patients (lanes 6–13) using CD138 magnetic beads. Total protein lysates (35 µg per lane) were subjected to Western blot analysis using 
anti–Bcl-B or Hsp60 antibodies. (D and E) Total protein extracts (30 µg) from a panel of human MM cell lines were subjected to SDS-PAGE/immunoblot using 
Bcl-B, Bcl-2, Mcl-1, and Actin antibodies (top). In parallel, bcl-b transcript level was determined by RT-PCR (bottom).
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protein is mainly dependent on its posttranscriptional regu‑
lation and that the abundance of the transcript does not re‑
flect the expression level of the protein (Beverly et al., 2012; 
van de Kooij et al., 2013; Rooswinkel et al., 2014). Collec‑
tively, these data suggest that Bcl‑B protein could be a ro‑
bust marker of MM disease.
Expression of Bcl-B in B cells drives MM in transgenic mice
To investigate the role of Bcl‑B in plasmocyte homeostasis, 
we designed transgenic mice carrying the Bcl‑B open read‑
ing frame under the control of the immunoglobulin VH pro‑
moter and Eµ enhancer elements (Eµ‑bcl‑b mice; Fig. 2 A). 
Among the eight founders obtained, we further analyzed 
those expressing the transgene exclusively in B cells. All of 
them developed an MM‑like disease. We further focused on 
the founder line with intermediate expression of Bcl‑B. As 
expected, the Eµ regulatory elements specifically drove ex‑
pression of Bcl‑B only in the BM, spleen, and lymph nodes 
(Fig. 2 B). Although endogenous Bcl‑B protein is absent in 
mice, the functionality of exogenous Bcl‑B protein was con‑
firmed in splenic cells isolated from Eµ‑bcl‑b mice based 
on its ability to interact with the BH3‑only family mem‑
ber Bim (not depicted).
The overall survival of homozygous (+/+) Eµ‑bcl‑b 
mice (Fig. 2 C, red curve) was significantly lower than that 
of control mice (Fig. 2 C, black curve). Half of the homo‑
zygous (+/+) Eµ‑bcl‑b mice died within 18 mo versus 26 
mo for the control mice. Moreover, all (+/+) Eµ‑bcl‑b mice 
were dead at 20 mo compared with only 10% of the control 
mice. Of note, hemizygous (−/+) Eµ‑bcl‑b mice showed an 
intermediate overall survival that correlated with the twofold 
lower Bcl‑B expression in the corresponding plasmocytes 
(Fig. 2 C, blue curve and inset). For the rest of the study, we 
used almost exclusively hemizygous (−/+) Eµ‑bcl‑b mice. 
With age, Eµ‑bcl‑b mice exhibited an increased proportion 
of CD138+ plasmocytes in their BM (Fig. 2 D). The increased 
proportion of CD138+ plasmocytes was also confirmed by 
immunofluorescence and by May‑Grünwald‑Giemsa (MGG) 
staining (not depicted). At 15 mo, the mean percentage of 
mature plasmocytes (B220−/CD138+) was 15.58% (with a 
range of 5% to 52%) in Eµ‑bcl‑b mice versus only 0.47% in 
control mice. Importantly, neither WT nor transgenic young 
mice developed plasmacytosis (not depicted). As is the case for 
MM patients who often develop anemia, Eµ‑bcl‑b mice ex‑
hibited reduced hemoglobin levels (mean = 7.5 g/dl, n = 28) 
compared with their control counterparts (mean = 13.2 g/dl, 
n = 16; Fig. 2 E). Although all aged Bcl‑B mice developed an 
MM‑like disease, the incidence of the splenomegaly in Eµ‑
bcl‑b mice was only 53.3% (not depicted). Splenomegaly was 
accompanied by an increase in cellularity and a significant in‑
crease in mature B cell number. However, we failed to detect 
any increase in CD138‑positive cells, corresponding to plas‑
mocytes, in the spleens of Eµ‑bcl‑b mice. At the same time, 
we identified a comparable proportion of T cells, B cells, and 
PCs in the lymph nodes of wild‑type and Eµ‑bcl‑b mice (not 
depicted). Moreover, Eµ‑bcl‑b mice exhibited characteristic 
lytic bone lesions (Fig. 2 F, top) compared with their control 
counterparts (Fig.  2  F, top). Indeed, areas of bone destruc‑
tion were clearly visible in Eµ‑bcl‑b mice (Fig. 2 F, yellow 
arrows). Tartrate‑resistant acid phosphatase (TRAP) staining 
was also analyzed in the trabecular zone of the femurs from 
WT and Eµ‑bcl‑b transgenic mice. The black arrows indicate 
significantly more TRAP‑positive osteoclasts (purple stain‑
ing) in Eµ‑bcl‑b mice. Images were analyzed to define the 
areas corresponding to TRAP staining. These areas were nor‑
malized to the bone areas and revealed a significant increase 
in TRAP‑positive cells in Eµ‑bcl‑b mice compared with WT 
mice (not depicted). Congo red staining of histochemical 
sections from the kidneys of wild‑type and Eµ‑bcl‑b mice 
showed reddish and intense orange deposits in the latter, cor‑
responding to amyloid deposition (Fig.  2 G, left). This was 
confirmed under polarized light (Fig. 2 G, right). The bright 
green is the “apple green birefringence” that is characteris‑
tic of amyloid deposition. Such deposits are also reminiscent 
of the human pathology.
Eµ-bcl-b mice exhibit monoclonal hypergammaglobulinemia
Serum protein electrophoresis (SPEP) on the blood of 18‑mo‑
old mice confirmed the diagnosis of myeloma (Fig. 3 A). The 
presence of a monoclonal spike (M‑spike; γ‑globulin peak) in 
transgenic mice is indicated by an arrow (Fig. 3 A). A promi‑
nent γ‑globulin peak was also detected in the sera of 9 out of 
11 mice, and a fainter one was present in the 2 remaining mice 
(Fig. 3 B). We also analyzed the appearance of the γ‑glob‑
ulin peak in the serum of transgenic mice as a function of 
the disease progression (Fig. 3 C). The immunoglobulin peak 
was faintly detected at 12 mo and was maximal after 18 mo 
of age, but undetectable in the serum of 24‑mo‑old control 
mice (Fig. 3 C). Densitometric analysis showed a time‑de‑
pendent increase of gammaglobulinemia in the serum of four 
transgenic mice and a parallel decrease in albumin production 
(Fig. 3 D). The decrease in serum albumin level is a hallmark 
of human MM that was reported in the previously generated 
MM mouse model (Chesi et al., 2008). A selective increase 
in IgG2b was detected by ELI SA in the sera of homozygous 
Eµ‑bcl‑b (n = 30) versus control mice (n = 15), whereas no 
increase in the IgG1 and IgG3 levels was noted (Fig. 3 E). 
IgA and IgM levels were significantly decreased in homozy‑
gous Eµ‑bcl‑b mice. This finding is in agreement with the 
situation observed in the human disease. Globally, from this 
data, we concluded that 86.7% of the homozygous Eµ‑bcl‑b 
mice developed a monoclonal gammopathy. In comparison, 
38.1% of the hemizygous transgenic mice developed a mono‑
clonal gammopathy (not depicted). To further confirm the 
monoclonal origin of the tumors that developed in the Eµ‑
bcl‑b transgenic mice, we analyzed immunoglobulin heavy 
and light chain gene rearrangements in sorted CD138+ plas‑
mocytes from two WT and three Eµ‑bcl‑b mice (compare 
Table S3). PCR analysis revealed the clonal origin of the 
tumor in homozygous transgenic mouse #1 for both IgH 
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Figure 2. Generation and characterization of Eµ-bcl-b transgenic mice. (A) Transgenic mice were designed that carry the Myc-bcl-b open reading 
frame under the control of the immunoglobulin VH promoter and Eµ enhancer elements (Eµ-bcl-b mice). (B) The Bcl-B protein level was analyzed by 
Western blot in the spleen, lymph node, thymus, BM, kidney, muscle, and heart of 8-wk-old control or Eµ-bcl-b transgenic mice. The asterisk indicates 
a nonspecific band used as a loading control. (C) The graph represents the overall survival (in months) of a cohort of 56 WT, 80 hemizygous (−/+), and 
48 homozygous (+/+) Eµ-bcl-b mice. Statistically significant differences (P < 0.005) were detected between Eµ-bcl-b transgenic and control littermates. 
(inset) Splenic cells from WT, (−/+), and (+/+) Eµ-bcl-b mice were collected and lysed, and the total protein extracts were subjected to SDS-PAGE/
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and Igk, with five identical clones out of five sequenced in 
each case. Regarding the second transgenic mouse (tumor 
#2), which was also supposed to be homozygous, the results 
for the monoclonality on the basis of the IgK locus appear 
very clear, whereas the results for the monoclonality on the 
basis of the IgH locus, where a dominant B cell clone popu‑
lation represents at least 50% of the myeloma cells, appear less 
clear. Therefore, one can consider mouse #2 as oligoclonal. 
Globally, there was good evidence of clonal expansion for 
both mouse #1 and #2 compared with WT mice. In contrast, 
for the third transgenic mouse (tumor #3), which was known 
to be hemizygous, the tumor was clearly polyclonal. This was 
not unexpected because two‑thirds of the hemizygous Eµ‑
bcl‑b transgenic mice produce more than one monoclonal 
antibody. Finally, sequence analysis of the VDJH4 and VKJK 
variable regions showed evidence of SHM and intraclonal di‑
versity accumulation, both compatible with a clonal expansion 
process. In conclusion, despite the low number of mice tested, 
a monoclonal origin was established for the two homozygous 
Eµ‑bcl‑b mouse tumors. Collectively, the results from Fig. 3 
and Table S3 confirm the monoclonality of the disease.
Set of genes modulated in Eµ-bcl-b plasmocytes
To compare gene expression profiles of control and Eµ‑bcl‑b 
mice, we performed dedicated microarrays covering the main 
cytokines affected in MM and important cellular pathways 
involved in B cell proliferation and differentiation. We ob‑
served a significant increase in the mRNA expression of key 
factors involved in the pathogenesis of human MM, including 
igf‑1, il‑6, and il‑7 cytokines; c‑myc, ccnd2, c‑maf, and c‑jun 
proto‑oncogenes; and irf‑4, prdm‑1, and xbp‑1 key genes in‑
volved in B cell and plasmocyte differentiation (Iida et al., 
1997; Borson et al., 2002; Klein et al., 2003; Shaffer et al., 
2008; Ohguchi et al., 2016). Of note, modulation of mRNA 
expression of the bone resorption factors rank, rank‑l, bmp‑6, 
and trap was also detected (Fig. 4). Collectively, this pattern of 
mRNA expression is in agreement with the MM phenotype 
developed by the Eµ‑bcl‑b mice.
The malignant PCs of Eµ-bcl-b mice are 
serially transplantable and are sensitive to 
conventional MM therapies
To determine whether the BM cells from Eµ‑bcl‑b mice have 
the potential to generate clinical features of MM into sec‑
ondary recipients, BM mononuclear cells from transgenic and 
control mice were i.v. injected into lethally irradiated synge‑
neic C57BL/6 mice. Conversely to mice transplanted with 
control BM cells, those transplanted with transgenic BM cells 
showed signs of weakness after 2 mo. The CD138+/B220− 
PC expansion was maintained in the BM of the first and 
second transplants (Fig. 5 A), and SPEP analysis detected a 
monoclonal peak in the sera of transplanted mice (Fig. 5 B). 
Blood analysis also revealed a drastic reduction in hemoglobin 
and hematocrit levels (Fig.  5 C). Mice serially transplanted 
with control BM cells had no evidence of plasmacytosis, IgG 
peak, or blood count anomalies. The clonogenic potential of 
BM cells from Eµ‑bcl‑b or wild‑type secondary transplanted 
mice was further analyzed. Only BM cells from Eµ‑bcl‑b 
mice harbored a high clonogenic potential and could be ex‑
panded in culture medium supplemented with mouse–ril‑7 
(Fig. 5, D–F). Indeed, after 14 d, the proportion of B220−/
CD138+ PCs in the BM of Eµ‑bcl‑b mice drastically in‑
creased (Fig.  5 G). All together, these findings confirm the 
tumorigenic nature of the Eµ‑bcl‑b mice plasmocytes.
To determine whether the Eµ‑bcl‑b are sensitive to con‑
ventional chemotherapies, 24‑mo‑old transgenic and control 
mice were treated with either VEL CADE (0.5 mg/kg twice 
a week for 6 wk) or melphalan (1.25 mg/kg once a day for 5 
wk; Fig. 5 H). At the end of both treatments, a drastic diminu‑
tion of the plasmacytosis in the BM from the transgenic mice 
was observed. In parallel, we showed that the B (B220+), T 
(CD4+/CD8+), and monogranulocytic (GR1+) populations 
were not affected by both treatments in BM or spleen from 
control or transgenic mice (not depicted). These results show 
that the tumorigenic plasmocytes from the Eµ‑bcl‑b mice 
are sensitive to conventional therapies and confirm that our 
model could be used to test innovative therapeutic strategies.
Increased plasmocyte proliferation and differentiation of 
Eµ-bcl-b splenic B cells
We next investigated the role of Bcl‑B in B cell prolifera‑
tion and plasmocyte differentiation ex vivo. Splenic B cells 
from 8‑wk‑old control and Eµ‑bcl‑b mice were incubated 
ex vivo with LPS. LPS significantly increased the number of 
B cells in wild‑type mice at 3 d (Fig. 6 A). Splenic B cells 
isolated from Bcl‑B mice exhibited a 2.5‑fold increase in B 
cell number in response to LPS, whereas non‑B cells were 
unaffected (Fig. 6, A and B). During plasmocyte differentia‑
immunoblot using Bcl-B and Hsp60 antibodies. (D, left) PCs from BM sections of hemizygous 18-mo-old WT or Eµ-bcl-b mice were stained with an an-
ti-CD138 antibody. (right) The infiltration of PCs into the BM of transgenic mice was confirmed by flow cytometry using B220 and CD138 antibodies. (E) 
Hemoglobin levels in the peripheral blood were measured in 18-mo-old WT mice (n = 16) and Eµ-bcl-b mice (n = 28). ***, P < 0.0001 using a two-tailed 
Student’s t test for unpaired data. Horizontal bars indicate median. (F, left) Freshly isolated nondecalcified femurs from WT and hemizygous Eµ-bcl-b 
transgenic mice were x-rayed. The yellow arrows indicate lytic bone lesions in Eµ-bcl-b mice. (right) TRAP staining was analyzed in the trabecular zone 
of the femurs from WT and Eµ-bcl-b transgenic mice. The black arrows indicate more TRAP-positive osteoclasts (purple color) in Eµ-bcl-b mice. (G) Renal 
tissue sections from 18-mo-old control (WT) and hemizygous Eµ-bcl-b mice were stained with Congo red. (left) Sections were mounted, and brightfield 
images were acquired. The black arrows indicate amyloid deposition in the interstitium. (right) Polarized images were also acquired. The bright green is 
the “apple green birefringence” that is characteristic of amyloid.
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Figure 3. Eµ-bcl-b transgenic mice exhibit monoclonal gammopathy. (A) SPEP was performed with the sera of representative 18-mo-old WT and 
hemizygous Eµ-bcl-b mice. The presence of an M-spike (γ-globulin peak) in the transgenic mice is indicated by an arrow. (B) SPEP was performed with the 
sera of 18-mo-old mice (3 control and 11 hemizygous Eµ-bcl-b transgenic mice). The positions of albumin and the different globulins are indicated. (C) SPEP 
was performed on WT and hemizygous Eµ-bcl-b mice at the indicated age (months). The positions of albumin and the different globulins are indicated. (D) 
Densitometric analysis of albumin and γ-globulin in the sera of four Eµ-bcl-b mice was performed. Note the hypergammaglobulinemia and hypoalbumin-
emia in hemizygous Eµ-bcl-b mice. (E) Sera from 18-mo-old WT (n = 15) or homozygous Eµ-bcl-b (n = 30) mice were analyzed by ELI SA. ***, P < 0.001; **, 
P < 0.01; *, P < 0.05 using a two-tailed Student’s t test for unpaired data. Results are expressed as the mean ± SD.
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Figure 4. Eµ-bcl-b mice exhibit an mRNA expression pattern that is compatible with the MM phenotype. Total RNA was obtained from sorted 
medullar plasmocytes of 18-mo-old control WT mice (n = 4) and transgenic hemizygous Eµ-bcl-b developing myeloma (n = 4) mice. The mRNA expression 
levels of genes implicated in growth, PC differentiation, and bone resorption were analyzed by quantitative RT-PCR. The expression levels were normalized 
accordingly to the ubiquitin and β-actin housekeeping genes. Where indicated, the cumulative data ± SD from independent experiments are shown. ***, P 
< 0.001; **, P < 0.005; *, P < 0.05, using a two-tailed Student’s t test for unpaired data.
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Figure 5. The malignant PCs of Eµ-bcl-b mice are serially transplantable and are sensitive to conventional MM therapies. Mononuclear cells 
from the BM of either hemizygous 24-mo-old transgenic mice or control mice were isolated and injected i.v. into lethally irradiated syngeneic C57BL/6 
mice. Two independent sets of recipient mice after a first and second serial transplant are represented. Transplanted mice were sacrificed at 3 mo. (A) The 
percentage of CD138+/B220− PCs in control or Eµ-bcl-b transplanted mice was determined by flow cytometry. (B) The presence of M-spike in the sera of 
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tion, B cells first exhibited increased expression of B220 (low 
to high) and next differentiated into B220+/CD138+ B cells 
(Fig. S1). Plasmocyte differentiation was assessed by follow‑
ing the emergence of B220+/CD138+ B cells in control and 
Eµ‑bcl‑b mice. LPS significantly increased the proportion of 
B220+ B cells in transgenic mice (Fig. 6 B). Quantification of 
CD138+ cells revealed the increased differentiation potential 
of B cells isolated from Eµ‑bcl‑b mice (Fig. 6 C). Collectively, 
these data show that Bcl‑B favors plasmocyte differentiation. 
Expressions of Xbp‑1 and PRDM1 were also analyzed be‑
cause these transcription factors are known to be essential 
for plasmocyte differentiation. Xbp‑1 has also been reported 
to drive MM in a transgenic mouse model (Carrasco et al., 
2007). Xbp‑1 and PRDM1 protein levels increased grad‑
ually during LPS‑induced plasmocyte differentiation and 
correlated with plasmocyte differentiation in Eµ‑bcl‑b mice 
(Fig. 6 D). CFSE staining experiments in splenocytes isolated 
from LPS‑treated wild‑type or Eµ‑bcl‑b mice showed that 
differentiation of B cells (B220+/CD138−) into immature 
plasmocytes (B220+/CD138+) was more efficient in trans‑
genic mice after 72 h. According to the release of CFSE, the 
inactive B220low/CD138− B cell population and B220low/
CD138+ mature plasmocytes from transgenic mice exhibited 
a strong increase in proliferative potential (Fig. 6 E). The pro‑
liferative potentials of active B220high/CD138− B cells and 
immature B220high/CD138+ plasmocytes were slightly in‑
creased in the Eµ‑bcl‑b mice. Finally, we performed exper‑
iments to determine whether the ability of Bcl‑B to inhibit 
B cell death was responsible for increased differentiation, pro‑
liferation, and survival. In the absence of LPS, we detected a 
strong increase in plasmocyte cell death that was significantly 
lowered in Eµ‑bcl‑b, whereas LPS induced a significant de‑
crease in plasmocyte cell death in wild‑type mice (Fig. 6 F). 
In addition, we observed marginal propidium iodide staining 
of plasmocytes from Eµ‑bcl‑b mice, confirming the key role 
of Bcl‑B in the protection against cell death. Identical results 
were observed for B cells (Fig. 6 F). No protection against cell 
death was detected in splenic T cells from wild type and Eµ‑
bcl‑b that did not express Bcl‑B (Fig. 6 F). Globally, our data 
establish a specific role for Bcl‑B in the differentiation and 
proliferation of plasmocytes through inhibition of cell death.
DIS CUS SION
Molecular analysis of both mouse and human MM has un‑
derscored the important role of the antiapoptotic members of 
the Bcl‑2 family in the pathogenesis of this disease. Among 
them, Bcl‑2 and Mcl‑1 expression levels have been reported 
to be increased in MM and to act as key factors in MM dis‑
ease progression and chemoresistance (Tu et al., 1998; Spets et 
al., 2002; Gomez‑Bougie et al., 2004; Wuillème‑Toumi et al., 
2005; Bodet et al., 2011; Morales et al., 2011). In the present 
study, we examined a large panel of MM cell lines to deter‑
mine the expression of Bcl‑2, Mcl‑1, and Bcl‑B (Fig. 1, D and 
E). Importantly, Bcl‑B protein level was homogeneous in all of 
the MM cell lines tested. Moreover, we clearly demonstrated 
that Bcl‑B protein is highly overexpressed in plasmocytes iso‑
lated from MM patients compared with those isolated from 
either healthy controls or MGUS patients. These results sug‑
gest that, in addition to Bcl‑2 and Mcl‑1, Bcl‑B protein may 
likely be a new marker of MM.
Owing to the importance of Bcl‑2 members in the 
MM disease, several animal transgenic models were generated 
in which these antiapoptotic proteins were expressed in the 
B cell compartment. Enforced expression of Bcl‑2 and Mcl‑1 
in B cells and hematopoietic cells, respectively, resulted in B 
cell malignancies displaying immature phenotype rather than 
MM (McDonnell and Korsmeyer, 1991; Zhou et al., 2001). 
Because Bcl‑XL is one of the most potent prosurvival proteins 
(Beverly and Varmus, 2009) and because Bcl‑XL is involved in 
chemoresistance processes in MM (Tu et al., 1998), a 3′KE/
Bcl‑XL mouse model was engineered. Enforced expression of 
Bcl‑XL in B cells at late stage resulted in nonmalignant PC 
foci in the BM and soft tissues without affecting the life span 
of transgenic mice (Linden et al., 2004). When deregulation 
of Bcl‑XL and of the c‑Myc oncogene was combined in the 
B cell compartment (3′KE/Bcl‑XL/Ig‑Myc), mice developed 
nonindolent PC tumors with short onset (135 d on average) 
and full penetrance (Cheung et al., 2004). These tumors pro‑
duced monoclonal Ig (IgG and IgM) and infiltrated BM as 
well as spleen. Moreover, PCs obtained from tissues with plas‑
macytosis were not transplantable into nude mice, suggesting 
that these cells had not yet undergone malignant transforma‑
tion. These results suggest that deregulation of Bcl‑XL either 
alone or in combination with c‑Myc oncogene in the B cell 
compartment does not drive a complete MM‑like disease.
Of the different transgenic mice models expressing an 
antiapoptotic Bcl‑2 member alone or together with c‑MYC 
in the B cell compartment, the Eµ‑bcl‑b model described 
herein is the only one that recapitulates most of the main 
features of the human MM pathology: reduction of life span, 
serially transplanted mice was determined by SPEP analysis. (C) Hemoglobin and hematocrit levels were measured on a Hemavet automated cell counter. 
The mean ± SD of three independent experiments is shown. (D) BM nucleated cells were isolated from 3-mo-old Eµ-bcl-b or WT secondary transplanted 
mice and were grown in semisolid methyl cellulose medium (5 × 103 cells/ml). Colonies were detected after 14 d of culture by adding 1 mg/ml MTT reagent. 
(E) Light microscopy images of colonies were also captured. Bars, 200 µm. (F) Colonies were counted using the ImageJ quantification software. (G) BM cells 
from Eµ-bcl-b mice were also maintained in culture in StemSpan SFEM medium supplemented with 1 ng/ml of recombinant mouse–IL-7, and the propor-
tion of PCs was determined by flow cytometry. (H) BM cells from 24-mo-old control and hemizygous Eµ-bcl-b mice were isolated, and the percentage of 
plasmocytes (CD138+) was determined by cytometry. Then, mice were treated with either VEL CADE (0.5 mg/kg twice a week for 6 wk) or melphalan (1.25 
mg/kg once a day for 5 wk). At the end of the experiment, mice were sacrificed and plasmacytosis was monitored by flow cytometry as described above. 
Where indicated, the cumulative data ± SD from independent experiments are shown. ***, P < 0.001, using a two-tailed Student’s t test for unpaired data.
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Figure 6. Eµ-bcl-b splenic cells show increased cell proliferation and differentiation. (A) Splenic B cells from hemizygous Eµ-bcl-b and WT mice 
were isolated and treated ex vivo for 1, 2, or 3 d with or without 8 µg/ml LPS. The cells were then harvested, and the number of B and T cells was deter-
mined by flow cytometry using a B220 antibody. (B) Splenic cells from hemizygous Eµ-bcl-b or WT mice were treated as in A. The cells were then harvested, 
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high penetrance of phenotype, indolent PC expansion re‑
stricted to the BM, monoclonal gammaglobulinemia for 
the great majority of the homozygous mice (M‑spike and 
unique IgG2b secretion), malignancy of the plasmocytes 
(transplantability into recipient mice), bone lytic lesions, renal 
immunoglobulin deposition, anemia, decreased albumin lev‑
els, and elevated expression of genes encoding proteins in‑
volved in MM pathogenesis.
Importantly, MM induction seems to be a unique fea‑
ture of Bcl‑B because the introduction of a prosurvival signal 
in the B cell compartment by other Bcl‑2 members, even 
more robust (Eµ‑bcl‑2 or 3′KE/bcl‑xL) than the one induced 
by Bcl‑B (Beverly and Varmus, 2009; Beverly et al., 2012), 
does not specifically lead to an MM‑like disease in mice.
From the M‑spike present in the sera of all the trans‑
genic mice tested (Fig. 3, B and C), it is obviously impossi‑
ble to extrapolate for a single VDJ rearrangement. However, 
(a) the ELI SA tests performed on a great number of trans‑
genic mice that specifically show the production of a unique 
monoclonal antibody (IgG2b), (b) the fact that Eµ‑bcl‑b mice 
always exhibit >10% tumoral plasmocytes, and (c) the clon‑
ality data presented in Table S3 argue strongly that Eu‑bcl‑b 
mice do develop an MM phenotype. In addition, SHM, a 
hallmark of MM, was also confirmed in a few mice (Table 
S3). The percentage of mutations was significantly higher in 
transgenic mice, and although we used a random polymerase 
for the assessment of the VDJ rearrangement, previous results 
from our team have shown a mean error of <0.3% using this 
polymerase, which is drastically lower than the frequency of 
mutation found in Eµ‑bcl‑b mice (unpublished data). These 
data convincingly show that Eµ‑bcl‑b mice display an MM 
phenotype that replicates accurately the human disease. An‑
other point of the present study is the specific expression of 
IgG2b by all Eµ‑bcl‑b homozygous mice. Despite the fact 
that around 10–15% of all human MM secrete this specific 
isotype, we found no likely reason either in the literature or 
in questioning experts in the field that could explain such a 
selective IgG2b expression.
Of note, the vk‑Myc mouse model of MM, in which the 
activation of c‑Myc oncogene occurs sporadically through‑
out the physiological SHM process, shares many common 
features with our Eµ‑bcl‑b mice. This model fulfills most of 
the biological and genetic criteria of an ideal mouse model 
of MM. Authors (Chesi et al., 2008) have argued that c‑myc 
activation could be the secondary event that further increases 
cell proliferation. One hypothesis could be that deregulation 
of Bcl‑B in plasmocytes might represent an important pri‑
mary prosurvival event necessary for the initiation of MM 
pathogenesis. This hypothesis is supported by the gene tran‑
scription profile that showed an increase of c‑myc mRNA 
in plasmocytes isolated from Eµ‑bcl‑b mice compared with 
control mice (Fig. 4). Table S4 summarizes the characteristics 
of the different MM‑like mouse models previously generated.
Compared with other prosurvival Bcl‑2 proteins, it was 
recently confirmed that Bcl‑B has the narrowest capacity to 
bind proapoptotic proteins (Bax, Bik, and Bim), highlighting 
a more specialized role in the apoptosis signaling (Rautureau 
et al., 2012). The proapoptotic Bcl‑2 protein Bim was re‑
ported to be essential for the maintenance of B cell homeo‑
stasis (Oliver et al., 2006; Huntington et al., 2009) through 
the elimination of autoreactive B cells (Enders et al., 2003; 
Fischer et al., 2007) and through its contribution to the dif‑
ferentiation of B cells into PCs (Gao et al., 2012). Moreover, 
expression of Bim and its association with the antiapoptotic 
Bcl‑2 members was also described as an important factor for 
the survival of Myeloma cells (Gomez‑Bougie et al., 2004; 
Romagnoli et al., 2009; Morales et al., 2011) and for the pre‑
dicted response to chemotherapy agents. Thus, the specific 
and potent inhibition of Bim‑induced cell death by Bcl‑B 
could partially explain why Eµ‑bcl‑b mice develop charac‑
teristic features of human MM.
In this context, a recent study suggested that the anti‑
apoptotic potency of Bcl‑2 proteins relies on their stability 
rather than their binding selectivity (Rooswinkel et al., 2014). 
Several studies are currently underway to better understand 
the mode of regulation of the Bcl‑B protein in cells. Recent 
reports showed that ubiquitination and proteasomal turnover 
dictate the expression level of the Bcl‑B protein and thereby 
its antiapoptotic activity (Beverly et al., 2012; van de Kooij et 
al., 2013; Rooswinkel et al., 2014). This work is in agreement 
with an alternative posttranslational stabilization mechanism 
as the main mode of Bcl‑B regulation in MM. Using CHX, 
a protein synthesis inhibitor, we recently measured the sta‑
bility of the Bcl‑B protein in several non‑MM and MM cell 
lines (unpublished data). We evaluated that the half‑life of the 
Bcl‑B protein in HeLa cells is ∼3 h, which is consistent with 
previous studies describing Bcl‑B as an unstable protein (Bev‑
erly et al., 2012; van de Kooij et al., 2013). In contrast, in MM 
and the percentages of inactive B cells (B220low/CD138−), active B cells (B220High/CD138−), and immature/mature PCs (CD138+) were determined by flow 
cytometry using B220 and CD138 antibodies. (C) The graph represents a quantification of the CD138-positive PCs after LPS treatment. (D) Splenic B cells 
from hemizygous Eµ-bcl-b and WT mice were treated as in A. The cells were then collected, washed, and lysed, and total protein extracts were subjected 
to SDS-PAGE/immunoblot using Bcl-B, Xbp-1, PRDM1, and Hsp60 antibodies. (E) Splenic B cells from hemizygous Eµ-bcl-b and WT mice were isolated and 
stained with CFSE dye. After 24 h, the cells were stimulated with 8 µg/ml LPS for 72 h to induce plasmocyte differentiation. The proliferative potentials of 
the different living populations (inactive B cells [B220low/CD138−], active B cells [B220High/CD138−], immature PCs [B220+/CD138+], and mature PCs (B220−/
CD138+]) were determined by flow cytometry. (F) Splenic B cells from hemizygous Eµ-bcl-b and WT mice were treated as in A. Unstimulated cells (top) or 
LPS-stimulated cells (bottom) were harvested, washed, and labeled using B220 and CD138 antibodies as well as propidium iodide (PI). The percentage of 
dead cells (PI positive) was measured by flow cytometry. Where indicated, the cumulative data ± SD from three independent experiments are shown. **, P 
< 0.01; *, P < 0.05, using a two-tailed Student’s t test for unpaired data.
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cells, Bcl‑B remains stable at 24 h, suggesting an abnormal sta‑
bility of this protein in this pathological context. Thus, even if 
the abnormal stability of the Bcl‑B protein in MM appears to 
be a cause of its overexpression, the exact mechanism remains 
to be clarified and will be the object of future studies.
Importantly, Eµ‑bcl‑b mice exhibit elevated expression 
of genes encoding proteins involved in MM pathogenesis that 
may contribute to the MM phenotype. A dedicated transcrip‑
tional profile of Eµ‑bcl‑b BM plasmocytes showed increased 
expression of proto‑oncogenes (ccnd2, c‑myc, c‑maf, and 
c‑jun) that are well reported to be deregulated in the human 
MM (Claudio et al., 2002; Davies et al., 2003), therefore con‑
firming the tumorigenic nature of the PCs we observed in our 
MM mouse model. The transcription factor xbp‑1, required 
for PC proliferation and differentiation, was also induced in 
transgenic mice (Carrasco et al., 2007). This positive modu‑
lation is in agreement with the exacerbated proliferation and 
differentiation potential we observed in the B lymphocytes 
and plasmocytes of our mouse model. We also observed in 
Eµ‑bcl‑b mice an increased expression of cytokines required 
for the survival and proliferation of PCs (il‑6, il‑7, and igf‑1) 
and factors involved in osteoclastogenesis, including trap, rank, 
and rank‑l. Among them, IL‑6 and IGF‑1 were obviously re‑
ported to be crucial for the survival and the proliferation of 
myeloma cells (Gaillard et al., 1997; Sprynski et al., 2009). IL‑6 
and IL‑7, which are excessively secreted by tumor PCs, were 
also described to induce rank‑l expression via stromal cells and 
thereby promote osteoclastogenesis (Giuliani et al., 2002). This 
perturbation of bone homeostasis is associated with the devel‑
opment of osteolytic lesions and the loss of bone volume ob‑
served in MM patients (Hjertner et al., 2006). Thus, increased 
mRNA expression of il‑6, il‑7, rank, and rank‑l in our MM 
model is compatible with the bone lytic lesions we underlined. 
In summation, this gene network, which includes proto‑onco‑
genes, master transcription factors involved in plasmocyte dif‑
ferentiation, cytokines implicated in plasmocyte survival, and 
proliferation and bone resorption factors, coincides strongly 
with the MM phenotype of our Eµ‑bcl‑b mice.
In conclusion, we report here that the Eµ‑bcl‑b trans‑
genic mouse is a relevant model of human MM that accu‑
rately recapitulates the pathogenesis of this hematopoietic 
malignancy. Our data also underscore an as of yet uniden‑
tified role for Bcl‑B in B cell proliferation and plasmocyte 
differentiation through its ability to impair B cell death and 
drive MM progression. High levels of Bcl‑B protein were also 
observed in patients with MM but not in healthy controls or 
patients with MGUS. As this model recapitulates accurately 
the human disease and is readily transplantable in secondary 
recipients, it represents a pertinent tool to validate new po‑
tential therapies for MM patients.
MAT ERI ALS AND MET HODS
Eµ-bcl-b transgenic mice
To drive the expression of the Bcl‑B protein in B cells, we used 
the pBlueScript II vector containing a mouse variable chain 
enhancer, a promoter (Eµ), a fragment of the rabbit β‑globin 
gene, and a polyadenylation signal sequence. The Myc‑tagged 
bcl‑b cDNA was amplified by PCR from the corresponding 
pcDNA3 plasmid (Luciano et al., 2007) using the following 
primers: forward 5′‑ATACTC GAGATG GAA CAG AAA CTC 
ATC TCT‑3′ and reverse 5′‑ATACTC GAGTCA TAA TAA 
TCG TGT CCA GAG‑3′. Each primer contains an Xho1 re‑
striction site. The pBlueScript–Myc‑bcl‑b vector was obtained 
by subcloning the Xho1‑digested Myc‑bcl‑b PCR fragment 
into the Xho1‑digested pBlueScript vector. After sequenc‑
ing, the vector sequence was excised by SacI–KpnI digestion, 
and the resulting linearized and purified sequence was micro‑
injected into pronuclei obtained from B6D2 mice (Service 
d’Experimentation Animale et de Transgénèse [SEAT], CNRS, 
Villejuif, Paris, France). Transgenic founders were crossed with 
C57BL/6N mice to generate lines. F1 transgenic progeny were 
crossed with C57BL/6N mice to maintain the lines, and the 
mice were kept in specific pathogen–free conditions at the 
C3M facility for all subsequent analyses. The described pheno‑
type of the Eµ‑bcl‑b mice was maintained through at least 10 
generations. Screening of the transgenic mice was performed 
by PCR analysis using a set of bcl‑b–specific primers (5′‑GCC 
AAC CTT TGT TCA TGGC‑3′ and 5′‑GTG GTG ACG CTC 
GTG ACC‑3′), and the expression of the Bcl‑B protein was 
confirmed by Western blot analysis of various tissues using an 
anti–Bcl‑B antibody (compare Table S1).
For the survival experiments, the mice were aged until 
they showed evident signs of tumors and/or discomfort and 
subsequently sacrificed. Sibling control mice were sacrificed 
at the same time or allowed to age further. Necropsy was 
performed to assess the presence of phenotypic abnormalities. 
Statistical analysis was performed using Prism software (Graph‑
Pad Software). Survival curves were generated using the Ka‑
plan‑Meier method. All animal studies and experiments were 
performed with the approval of the Comité Institutionnel 
d’Ethique Pour l’Animal de Laboratoire (CIE PAL) and were in 
agreement with all regulatory standards. After the eradication 
of all our mice, the Eµ‑bcl‑b strain has been now rederived 
(JAN VIER Labs; project number 15.355), so that this model 
will be fully available for the scientific community in 2017.
Cell lines
The human MM cell lines U266, MM1.S, NCI‑H929, 
RPMI8226, ARH‑77, AF‑10, and OPM2 were purchased 
from ATCC. The LP‑1 cell line was obtained from DSMZ. 
The JIM3, XG‑1, XG‑2, XG‑5, XG‑7, MDN, JIM‑3, Nan‑1, 
Nan‑3, Nan‑8, BCN, and SBN cell lines were provided by 
M. Amiot (INS ERM U892, Nantes, France). All cells were 
cultured in RPMI‑1640 medium containing 10% fetal bo‑
vine serum, 50 U/ml penicillin, 50 mg/ml streptomycin, and 
1 mM sodium pyruvate (Gibco).
Western blot analysis
Whole cell extracts from BM, splenocytes, snap‑frozen tissues, 
and MM cell lines were lysed at 4°C in lysis buffer (50 mM 
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Hepes, pH 7.4, 150 mM NaCl, 20 mM EDTA, 100 µM NaF, 
10 µM Na3VO4, 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml 
aprotinin, and 1% Triton X‑100). The lysates were centrifuged 
at 16,000 g for 15 min at 4°C, and the supernatants were sup‑
plemented with SDS sample buffer. A total of 30 µg of proteins 
was separated on a 12% SDS–polyacrylamide gel and trans‑
ferred onto PVDF membranes (GE Healthcare) in 20 mM 
Tris, 150 mM glycine, and 20% ethanol buffer. After blocking 
nonspecific binding sites in saturation buffer (50 mM Tris, pH 
7.5, 50 mM NaCl, 0.15% Tween, and 5% BSA), the membranes 
were probed with primary antibodies (compare with Table S1) 
according to standard procedures. The membranes were then 
washed three times using TNA–1% NP‑40 (50 mM Tris, pH 
7.5, and 150 mM NaCl) and incubated further for 1 h with 
HRP‑conjugated antibodies. Bound immunoglobulins were 
detected using ECL detection solution (GE Healthcare).
Flow cytometry
Single‑cell suspensions from spleens, thymuses, and BM were 
collected, and red blood cells were lysed by ammonium 
chloride treatment (Sigma‑Aldrich). 106 cells were washed 
in PBS (0.5% BSA and 2  mM EDTA) and stained for 30 
min on ice with a combination of the indicated antibodies 
(compare with Table S1). Then, the cells were washed twice 
and resuspended in PBS (0.5% BSA and 2  mM EDTA). 
Multicolor flow cytometric analysis was performed using 
a MAC SQuant cytometer (Miltenyi Biotec) and analyzed 
with MAC SQuant software.
Isolation of PCs from patients
CD138+ BM cells were isolated from patients using magnetic 
CD138 microbeads (Miltenyi Biotec) according to the man‑
ufacturer’s instructions. In brief, patient samples were col‑
lected in tubes containing EDTA. Then, the cells were passed 
through a filter (100‑µm pore size) to remove bone fragments 
or cell clumps. The cells were then centrifuged at 445 g for 10 
min at room temperature in a swinging bucket rotor with the 
brake off. The supernatant was aspirated, and the cells were 
incubated with 50 µl of whole blood CD138 microbeads per 
1 ml of anticoagulated BM for 15 min at 4°C. The cells were 
then washed and resuspended in autoMACS running buffer. 
The magnetic separation was performed using the Possel WB 
program on the autoMACS Pro Separator. The purity of the 
isolated PCs was assessed by flow cytometry using an anti–
human CD138 antibody (compare with Table S1).
Treatment of Eµ-bcl-b mice with VEL CADE and melphalan
Eµ‑bcl‑b mice with significant plasmacytosis (>15%) were 
selected for drug treatment (five mice per group). 0.5 mg/
kg VEL CADE was given twice a week for 6 wk. 1.25 mg/
kg melphalan was given once a day (5 d per week) for 5 wk. 
Treatments with VEL CADE and melphalan were adminis‑
trated intraperitoneally with insulin syringe. At the end of the 
experiment, mice were sacrificed, and the BM plasmacytosis 
was quantified by flow cytometry.
Isolation of PCs from mice
The isolation of mouse PCs was performed with a CD138+ 
PC isolation kit (Miltenyi Biotec) according to the manufac‑
turer’s instructions. In brief, cells were extracted from tibia and 
femora of either Eµ‑bcl‑b or control mice, and the isolation 
of mouse PCs was performed in a two‑step procedure. First, 
non‑PCs were magnetically labeled with a cocktail of bio‑
tin‑conjugated antibodies (CD49b and CD45R) and anti‑bi‑
otin microbeads. Cells were then separated with autoMACS 
Separator (program Depl025). In the second step, PCs con‑
tained in the negative fraction were directly labeled with 
CD138 microbeads and isolated by positive selection (program 
Posseld2). The purity of the isolated PCs was assessed by flow 
cytometry using anti–mouse CD138 and B220 antibodies.
Ex vivo culture of splenocytes
8–10‑wk‑old WT or Eµ‑bcl‑b mice were euthanized, and sin‑
gle‑cell splenocyte suspensions were obtained by dissociation 
of the corresponding spleen. After red blood cell lysis with 
ammonium chloride (Sigma‑Aldrich), the splenocytes were 
counted and plated at a density of 5 × 105 cells/ml in sple‑
nocyte medium (RPMI‑1640 medium containing 10% fetal 
bovine serum, 50 U/ml penicillin, 50 mg/ml streptomycin, 
1 mM sodium pyruvate, and 50 µM 2‑ME). Then, the sple‑
nocytes were incubated with 8 µg/ml LPS serotype B4 (Sig‑
ma‑Aldrich). The experiment was terminated after 1, 2, or 3 d.
In vitro proliferation assay
B220+ splenocytes were incubated with 5 µM Cell Trace CFSE 
(Invitrogen) for 15 min at 37°C according to the manufactur‑
er’s instructions. Then, the cells were washed and plated in the 
splenocyte medium described in the previous section. After 
18 h, the cells were washed and plated in the same medium in 
the presence or absence of 8 µg/ml LPS and grown for 1, 2, 
or 3 d. The cells were then harvested and washed, and B cells 
were phenotyped using anti–mouse B220 and anti–mouse 
CD138 antibodies (compare Table S1). In parallel, the prolifer‑
ative potential (as measured by CFSE release) of the different 
living populations was determined by flow cytometry.
Colony formation assay
BM nucleated cells were isolated from the femora and tibia 
of Eµ‑bcl‑b or WT recipient mice. After red blood cell lysis 
with ammonium chloride (Sigma‑Aldrich), BM cells were 
grown in semisolid methyl cellulose medium (0.5 × 103 cells/
ml; MethoCult M3630; STE MCE LL Technologies). Colo‑
nies were visualized after 14 d of culture by adding 1 mg/ml 
3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bro‑ 
mide (MTT) reagent and were counted using the ImageJ 
quantification software (National Institutes of Health).
Ex vivo culture of BM cells
BM nucleated cells were isolated from the femora and tibia 
of Eµ‑bcl‑b or WT recipient mice. After red blood cell lysis 
with ammonium chloride (Sigma‑Aldrich), the BM cells 
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were counted and plated at a density of 5 × 105 cells/ml in 
StemSpan SFEM medium (STE MCE LL Technologies) sup‑
plemented with 1 ng/ml recombinant mouse–IL‑7 (Miltenyi 
Biotec). Cells were maintained in culture for 14 d.
Quantitative reverse transcription PCR
Total RNA was prepared from the BM cells of 18‑mo‑old 
transgenic mice or their control littermates using TRIzol re‑
agent according to the manufacturer’s instructions (Invitro‑
gen). Total RNA (1 µg) was reverse transcribed into cDNA 
using Superscript II reverse transcription (Invitrogen). Quan‑
titative PCR was performed using 100 ng cDNA and Power 
SYBR Green PCR Master Mix (Applied Biosystems). Each 
sample was run in triplicate in a Step One Plus Real‑Time 
PCR System (Applied Biosystems). The primers used are 
listed in Table S2. The expression levels were normalized to 
that of the ubiquitin and β‑actin housekeeping genes. The 
results were analyzed using the comparative 2−ΔΔCt method, 
with WT expression normalized to 1.
IgVH rearrangement and SHM analysis
The rearranged immunoglobulin variable heavy‑chain re‑
gion (IgVH) genes were amplified from DNA isolated from 
purified tumor and normal PCs by PCR. Forward primers 
that anneal to framework region III of the most abundantly 
used Igh‑VJ558 and Igh‑V7183 were used in separate reac‑
tions (covering >80% of the rearrangements) along with a 
reverse primer downstream of JH4. Immunoglobulin kappa 
light (IgK) chain rearrangements were PCR amplified using 
VK consensus primers and a reverse primer downstream of 
JK5. The PCR conditions were 40 cycles of 95°C for 30 s, 
60°C for 45 s, and 72°C for 90 s. PCR products indicative 
of clonal rearrangements were gel purified using the Wizard 
Gel and PCR clean‑up kit (Promega) and were sequenced 
directly using the same primers as in the PCR reaction and 
then further cloned using the PGEm‑T Easy kit (Promega). 
5–10 clones were sequenced for each PCR fragment to 
evaluate the clonal dominance of a given rearrangement. To 
determine IgV rearrangement and calculate the mutation 
frequency, sequences were aligned to the NCBI databases 
(IgBlast) and confirmed using the international ImMunoGe‑
neTics information system (IMGT) database. PCR for IgH 
and IgK was repeated two or three times for each sample to 
confirm the presence of dominant PCR fragments in tumors 
and of polyclonal patterns in WT PCs. As a control, DNA 
extracted from mouse normal PCs were analyzed in parallel 
to calculate the SHM rate.
X-ray analysis, TRAP staining, histopathology, 
and immunohistochemistry
Bone x‑ray radiography was performed on aged WT and Eµ‑
bcl‑b freshly isolated non‑decalcified femurs using the Fax‑
itron x‑ray Edimex System and AGFA HDR 37F9H films.
Kidneys were fixed in 4% paraformaldehyde for 2 h at 
room temperature and then overnight at 4°C. Fixed tissues 
were embedded into optimal cutting temperature media 
(OCT) and frozen in liquid nitrogen. OCT blocks con‑
taining the tissues were stored at −80°C until they were 
sectioned. Using a Leica cryostat CM350 (C3M histol‑
ogy facility, Nice), 10‑ to 15‑µm sections were collected. 
The tissue sections were incubated for 1 h with 1% Congo 
red solution, rinsed in water, and cleared in alkaline alco‑
hol until a clear background was obtained. Nuclei were 
then labeled with Harris hematoxylin for 30  s and rinsed 
in running water for 5–10 min. Sections were mounted 
in glycerol‑based solution, and brightfield and polarized 
images were acquired on a Leica DM5500B microscope 
equipped with a polarizer and a color camera (C3M light 
microscopy facility, Nice).
Femurs were fixed and decalcified in Bouin’s fixative 
solution (Labonord). After decalcification, the bones were de‑
hydrated through a graded alcohol series and xylene and sub‑
sequently embedded in paraffin. 5‑µm sections were cut and 
stained with hematoxylin and eosin (H&E). Immunohisto‑
chemistry was performed using a BenchMark XT Automated 
IHC Slide Staining System (Ventana; Roche) according to 
standard procedures. Dewaxed tissue sections were stained 
using an anti–mouse CD138 rat polyclonal antibody followed 
sequentially by mouse anti–rat biotinylated and streptavidin 
HRP antibodies (compare with Table S1).
TRAP staining
Femora were fixed in 4% paraformaldehyde for 24 h at 4°C, 
decalcified in 10% EDTA for 10 d at 4°C, and incubated over‑
night in a 30% sucrose solution, and 7‑µm sections were ob‑
tained with a cryotome (Shandon; Thermo Fisher Scientific). 
Bone sections were stained for TRAP activity using a leuko‑
cyte acid phosphatase kit (Sigma‑Aldrich) and hematoxylin, 
and staining was visualized by light microscopy (Palm Micro 
Beam; ZEI SS). TRAP staining was analyzed in the trabecu‑
lar zone of the femora as described (Mansour et al., 2011): 
images were analyzed using ImageJ software (W. Rasband, 
National Institutes of Health Image System) to define the 
areas corresponding to TRAP staining. These areas were nor‑
malized to the bone areas.
Hemoglobin, paraprotein (SPEP), and 
immunoglobulin measurement
Peripheral blood from WT and Eµ‑bcl‑b mice was collected 
into tubes containing EDTA (Greiner Bio‑One). Hemoglo‑
bin levels were measured on a Drew Hemavet 950FS and 
compared using the two‑tailed Student’s t test for unpaired 
data. For paraprotein measurement, the mice were bled by 
tail grazing. Then, the blood was collected, and the sera were 
harvested after blood coagulation and centrifugation for 10 
min at 1,000 g. The sera were diluted 1:2 in barbital buffer 
(60 mM Tris, 10 mM barbital, 50 mM Na‑diethyl‑barbituric 
acid, 0.5 µM thimerosal). Then, the sera were loaded onto gels 
and separated by electrophoresis (1% agarose [Euromedex] 
polymerized in barbital buffer). The gels were stained with 
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amido black and destained with acetic acid. For immunoglob‑
ulin measurement, the sera were diluted 1:50, and the total 
Ig concentrations were determined using an Ig subtype–spe‑
cific ELI SA quantification kit (Thermo Fisher Scientific). It 
has been reported that some anti‑IgG2a could cross‑react 
with IgG2c. Nevertheless, there was no difference between 
IgG2a expression between WT and transgenic mice, ruling 
out the possibility of an increased expression of IgG2c. This 
means that IgG2b is the only monoclonal antibody overex‑
pressed in the Eµ‑bcl‑b mice.
BM transplantation
BM nucleated cells were isolated from Eµ‑bcl‑b or WT 
femora and tibia donor mice. Then, 20 million cells were 
resuspended in 100  µl PBS and transplanted by i.v. injec‑
tion into the tails of 10‑wk‑old WT C57BL/6 recipient 
mice irradiated with 7Gy.
Statistical analysis
The results are expressed as the mean ± SD. The data were 
compared by one‑way ANO VA and Student’s t tests, and 
the Bonferroni correction was applied used GraphPad Prism 
software. Statistical significance was established at ***, P < 
0.0001; **, P < 0.01; *, P < 0.05. Survival rates were com‑
pared with the Kaplan‑Meier method using Prism software.
Study approval
BM samples from healthy, MGUS, or myeloma patients were 
obtained from the Internal Medicine or Hematology Depart‑
ments of the Centre Hospitalier Universitaire de Nice after 
informed consent was obtained (clinical trial NCT01270009). 
Mouse experiments were approved by the Institutional Ani‑
mal Care and Use committee of the University of Nice So‑
phia‑Antipolis (Nice, France).
Online supplemental material
Fig. S1 shows a schematic representation of B cell activation 
and differentiation after LPS stimulation. Table S1 shows a 
list of antibodies used for flow cytometry, Western blot, and 
immunochemistry. Table S2 shows a list of primers used 
for quantitative PCR. Table S3 shows IgH and IgK gene 
rearrangement and somatic mutations in mouse tumors. 
Table S4 shows a comparison of the biological and clinical 
features of available MM mouse models. Online supplemental 
material is available at http ://www .jem .org /cgi /content 
/full /jem .20150983 /DC1.
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